培美曲塞联合洛铂治疗肺腺癌的近期疗效和安全性研究

目的：评价国产培美曲塞联合国产洛铂一线治疗中晚期肺腺癌的近期疗效和毒副作用。方法：对40例经病理确诊为中晚期肺腺癌患者,国产培美曲塞500mg／m2,静脉滴入,d1;国产洛铂30mg／m2,静脉滴入,d1,21d为1个周期,并口服地塞米松、叶酸和肌肉注射维生素B12以减轻毒副作用。按照1981年wH0实体瘤疗效评定标准评价有效率、无进展生存期和毒副作用。结果：40例患者中,完全缓解2例（5．0％）,部分缓解16例（40．0％）,稳定13例（32．5％）,疾病进展9例（22．5％）,总有效率为45．0％（18／40）,疾病控制率为77．5％（31／40）,中位无进展生存期5．6个月。ⅢB和Ⅳ期患者之间的疗效没有明显差异。与药物相关的不良反应主要为Ⅰ／Ⅱ度骨髓抑制和胃肠道反应。Ⅲ／Ⅳ度毒性作用发生率仅2例（5．0％）,无脱发、肾毒性及神经毒性发生。结论：国产培美曲塞联合国产洛铂一线治疗中晚期肺腺癌具有较好的疗效和安全性。

Efficacy and safty of pemetrexed combined with lobaplatin treating patients with lung adenocarcinoma

OBJECTIVE： To evaluate the efficacy and safety of domestic pemetrexed and domestic luoplatin in the treatment of the patients with mid-advanced lung adenocarcinoma in the first line. METHODS.. A total of 40 patients with pathologically confirmed adenocarcinoma, received pemetrexed 500 mg/m2 and lobaplatin 30 mg/m2 , d1 , iv drip, 21 days per cycle. The patients received oral dexamethasone, oralfolic acid and im vitamin Blz supplementation to alleviate toxicity. The anti-tumor effect, response rate and toxicity of the drugs were measured by the WHO criteria published in 1981. RESULTS： In 40 patients, 2 cases CR（5.0%） ,16 cases PR（40.0%）, 13 cases SD（32.5%） and 9 cases PD（22.5~） ~The objective response rate was 45.0 M （18/40）. The disease control rates was 77.5 % （31/40）. The median progression free survival time（mPFS） was 5.6 months. No differences of response was found as compared stage Ⅲ B with Igpatients. The drug-related adverse reactions were mainly gradeⅠ /Ⅱ marrow toxicity and gastrointestinal response; The grade Ⅲ/Ⅳ incidence of toxicity were 2 cases（5.0%） ;hair lose, kidney toxicity and neurotoxicity were 0. CONCLUSIONS： The regi- ment of pemetrexed combined with lobaplatin is effective and safe in the treatment of mid-advanced patients with lung ade- nocarcinoma in the first line.